Trial Profile
A study to determine the maintenance of efficacy of agomelatine (25 mg to 50 mg) to prevent relapse in out-patients with Major Depressive Disorder. A 8 to 10 weeks open period treatment with agomelatine (25 mg to 50 mg) followed by 24 weeks randomised double-blind period, placebo-controlled, parallel groups and 20 weeks of optional double-blind treatment period.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Sep 2019
Price :
$35
*
At a glance
- Drugs Agomelatine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors IRIS; Servier
- 01 Aug 2009 Results published in the Journal of Clinical Psychiatry.
- 03 Sep 2008 Endpoint 'Hamilton Depression Rating Scale' has been met. Results presented at ECNP
- 19 May 2007 New trial record.